Antibodies and methods for WNT pathway-related diseases
US9296826B2 · kind B2 · utility
3Cited by
0References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 12, 2012 |
| Grant date | Mar 29, 2016 |
| Priority date | — |
| Expiry date | Oct 25, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y603/02019
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The transmembrane E3 ubiquitin ligases ZNRF3 and RNF43 are negative regulators of β-catenin and the Wnt signaling pathway in eukaryotic cells. The activity of ZNRF3 can be modulated by antibody binding to its extracellular domain, thus causing an increase in Wnt signaling. The ZNRF3 antagonizing antibodies can be used to treat diseases with low Wnt signaling, such as short bowel syndrome, osteoporosis, diabetes, neurodegenerative diseases, and mucositis. In addition, the antagonizing antibodies of the invention can be used to enhance Wnt signaling for tissue repair and wound healing.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.